Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial.

Journal of cosmetic dermatology·2025
Same author

Unilateral Extragenital Lichen Sclerosus Following Blaschko's Lines.

Clinical case reports·2024
Same author

Facial Merkel cell carcinoma in a 92-year-old man: A case report.

Clinical case reports·2024
Same author

A case of porokeratosis with a variety of morphological manifestations.

Clinical case reports·2024
Same author

Characterization of CM-Dil-labeled Muse cells in culture and in skin wounds in rats.

Cell and tissue banking·2023
Same author

Natural products of medicinal plants: biosynthesis and bioengineering in post-genomic era.

Horticulture research·2022

Related Experiment Video

Updated: May 14, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Integrative Multi-Omics Analysis and Computational Modeling Identifying Shared Inflammatory Pathways and JAK

Hui Yao1, Yi Wu1, Ruzhi Zhang1

  • 1Department of Dermatology, The Second Affiliated Hospital of Wannan Medical University, Wuhu 241000, China.

International Journal of Molecular Sciences
|May 13, 2026
PubMed
Summary

This study links inflammatory bowel disease (IBD) and pyoderma gangrenosum (PG) via shared molecular pathways, identifying JAK inhibitors like baricitinib as potential targeted therapies for this gut-skin axis comorbidity.

Keywords:
JAK-STAT signaling pathwaydrug repurposinginflammatory bowel diseasemolecular dockingmulti-omics integrated analysispyoderma gangrenosum

Related Experiment Videos

Last Updated: May 14, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Area of Science:

  • Computational Biology
  • Immunology
  • Genetics

Background:

  • Pyoderma gangrenosum (PG) and inflammatory bowel disease (IBD) share clinical comorbidities, but underlying molecular mechanisms are unclear.
  • Lack of mechanistic evidence exists on whether Janus kinase (JAK) inhibitors target shared pathological pathways in these comorbid conditions.

Purpose of the Study:

  • To investigate shared molecular mechanisms between PG and IBD.
  • To evaluate the therapeutic potential of JAK inhibitors in targeting these shared pathways.

Main Methods:

  • Integrated multi-omics data (transcriptomics, single-cell, GWAS) from PG and IBD.
  • Employed computational biology approaches: Mendelian randomization, network analysis, molecular docking, and system dynamics modeling.

Main Results:

  • Identified IBD as a causal risk factor for PG, pinpointing six shared genetic loci.
  • Revealed a conserved inflammatory module centered on the JAK-STAT pathway, with JAK2 and STAT3 as key hubs.
  • Baricitinib showed high affinity for JAK1/JAK2 and effectively suppressed the shared inflammatory network in silico.

Conclusions:

  • Established the molecular basis of the gut-skin axis comorbidity between PG and IBD through multi-omics integration.
  • Provided computational evidence supporting JAK inhibitors, particularly baricitinib, for targeted comorbidity therapy.
  • Highlighted the potential for mechanism-guided precision treatment strategies, pending experimental validation.